Biotech heads towards big catalysts
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
Astra tentatively takes Tigit pivotal
Bispecifics targeting Tigit and CTLA4 head into phase 3 development, as the developer follows Bristol out of IL-12.